Please select the option that best describes you:

What is your approach to screening for malignancy in dermatomyositis patients who do not have a high risk antibody profile and whose disease responds well to treatment?   

Do you pursue screening beyond age-appropriate malignancy screening, especially in younger patients? For how long do you continue to monitor beyond the initial screen? 



Answer from: at Community Practice
Sign in or Register to read more